782 related articles for article (PubMed ID: 16502484)
1. Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance.
Lee K; Park KH; Jeong SH; Lim HS; Shin JH; Yong D; Ha GY; Chong Y; KONSAR group
Yonsei Med J; 2006 Feb; 47(1):43-54. PubMed ID: 16502484
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004.
Lee K; Lim CH; Cho JH; Lee WG; Uh Y; Kim HJ; Yong D; Chong Y;
Yonsei Med J; 2006 Oct; 47(5):634-45. PubMed ID: 17066507
[TBL] [Abstract][Full Text] [Related]
3. Increasing prevalence of vancomycin-resistant enterococci, and cefoxitin-, imipenem- and fluoroquinolone-resistant gram-negative bacilli: a KONSAR study in 2002.
Lee K; Kim YA; Park YJ; Lee HS; Kim MY; Kim EC; Yong D; Chong Y;
Yonsei Med J; 2004 Aug; 45(4):598-608. PubMed ID: 15344199
[TBL] [Abstract][Full Text] [Related]
4. Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007.
Lee K; Lee MA; Lee CH; Lee J; Roh KH; Kim S; Kim JJ; Koh E; Yong D; Chong Y;
Yonsei Med J; 2010 Nov; 51(6):901-11. PubMed ID: 20879058
[TBL] [Abstract][Full Text] [Related]
5. Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009.
Lee K; Kim MN; Kim JS; Hong HL; Kang JO; Shin JH; Park YJ; Yong D; Jeong SH; Chong Y;
Yonsei Med J; 2011 Sep; 52(5):793-802. PubMed ID: 21786445
[TBL] [Abstract][Full Text] [Related]
6. Increasing prevalence of vancomycin-resistant Enterococcus faecium, expanded-spectrum cephalosporin-resistant Klebsiella pneumoniae, and imipenem-resistant Pseudomonas aeruginosa in Korea: KONSAR study in 2001.
Lee K; Jang SJ; Lee HJ; Ryoo N; Kim M; Hong SG; Chong Y;
J Korean Med Sci; 2004 Feb; 19(1):8-14. PubMed ID: 14966334
[TBL] [Abstract][Full Text] [Related]
7. Differential correlation between rates of antimicrobial drug consumption and prevalence of antimicrobial resistance in a tertiary care hospital in Greece.
Iosifidis E; Antachopoulos C; Tsivitanidou M; Katragkou A; Farmaki E; Tsiakou M; Kyriazi T; Sofianou D; Roilides E
Infect Control Hosp Epidemiol; 2008 Jul; 29(7):615-22. PubMed ID: 18624668
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone.
Lee K; Lee HS; Jang SJ; Park AJ; Lee MH; Song WK; Chong Y;
J Korean Med Sci; 2001 Jun; 16(3):262-70. PubMed ID: 11447969
[TBL] [Abstract][Full Text] [Related]
9. Increase in the Prevalence of Carbapenem-Resistant Acinetobacter Isolates and Ampicillin-Resistant Non-Typhoidal Salmonella Species in Korea: A KONSAR Study Conducted in 2011.
Yong D; Shin HB; Kim YK; Cho J; Lee WG; Ha GY; Choi TY; Jeong SH; Lee K; Chong Y;
Infect Chemother; 2014 Jun; 46(2):84-93. PubMed ID: 25024870
[TBL] [Abstract][Full Text] [Related]
10. Korean nationwide surveillance of antimicrobial resistance in 2000 with special reference to vancomycin resistance in enterococci, and expanded-spectrum cephalosporin and imipenem resistance in gram-negative bacilli.
Lee KW; Kim MY; Kang SH; Kang JO; Kim EC; Choi TY; Chong YS;
Yonsei Med J; 2003 Aug; 44(4):571-8. PubMed ID: 12950110
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
Morfin-Otero R; Noriega ER; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651
[TBL] [Abstract][Full Text] [Related]
12. Changes in the incidence and antimicrobial susceptibility of healthcare-associated infections in a New York hospital system, 2006-2012.
Cohen B; Liu J; Larson E
J Prev Med Hyg; 2017 Dec; 58(4):E294-E301. PubMed ID: 29707660
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study.
Seifert H; Blondeau J; Dowzicky MJ
Int J Antimicrob Agents; 2018 Oct; 52(4):474-484. PubMed ID: 30012439
[TBL] [Abstract][Full Text] [Related]
14. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
[TBL] [Abstract][Full Text] [Related]
15. Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases.
Ishikawa K; Hamasuna R; Uehara S; Yasuda M; Yamamoto S; Hayami H; Takahashi S; Matsumoto T; Minamitani S; Kadota J; Iwata S; Kaku M; Watanabe A; Sunakawa K; Sato J; Hanaki H; Tsukamoto T; Kiyota H; Egawa S; Deguchi T; Matsumoto M; Tanaka K; Arakawa S; Fujisawa M; Kumon H; Kobayashi K; Matsubara A; Wakeda H; Amemoto Y; Onodera S; Goto H; Komeda H; Yamashita M; Takenaka T; Fujimoto Y; Tsugawa M; Takahashi Y; Maeda H; Onishi H; Ishitoya S; Nishimura K; Mitsumori K; Ito T; Togo Y; Nakamura I; Ito N; Kanamaru S; Hirose T; Muranaka T; Yamada D; Ishihara S; Oka H; Inatomi H; Matsui T; Kobuke M; Kunishima Y; Kimura T; Ichikawa T; Kagara I; Matsukawa M; Takahashi K; Mita K; Kato M; Okumura K; Kawanishi H; Hashimura T; Aoyama T; Shigeta M; Koda S; Taguchi K; Matsuda Y
J Infect Chemother; 2015 Sep; 21(9):623-33. PubMed ID: 26166322
[TBL] [Abstract][Full Text] [Related]
16. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
Streit JM; Jones RN; Sader HS; Fritsche TR
Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
[TBL] [Abstract][Full Text] [Related]
17. [Causative agents of intravenous catheter-related infections and their antibiotic susceptibilities].
Aktaş E; Sarı EN; Seremet Keskin A; Pişkin N; Külah C; Cömert F
Mikrobiyol Bul; 2011 Jan; 45(1):86-92. PubMed ID: 21341163
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial resistance of selected invasive bacteria in a tertiary care center: results of a prospective surveillance study.
Djuric O; Jovanovic S; Stosovic B; Tosic T; Jovanovic M; Markovic-Denic L
J Infect Dev Ctries; 2016 Dec; 10(12):1325-1331. PubMed ID: 28036312
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
Kanj SS; Whitelaw A; Dowzicky MJ
Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
